Form 4: Immunome Inc. Director Sandra M. Swain Reports Stock Option Grant
SEC Form 4 Filing
Director Sandra M. Swain reports the acquisition of stock options in Immunome Inc.
Summary
- Sandra M. Swain, a director of Immunome Inc. (IMNM), filed a Form 4 on June 18, 2024, reporting a transaction.
- On June 13, 2024, Swain acquired 11,333 stock options with an exercise price of $16.04.
- These options vest in four quarterly installments starting June 13, 2024, and expire on June 12, 2034.
- Following the transaction, Swain directly owns 11,333 derivative securities.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing regarding stock option grants, indicating a neutral sentiment.
Positives
- The grant of stock options to a director aligns their interests with those of the shareholders.
Industry Context
Stock option grants are a common practice in the biotechnology industry to incentivize and retain key personnel.
Stakeholder Impact
- The stock option grant could potentially dilute existing shareholders if the options are exercised.
Key Dates
| Date | Description |
|---|---|
| 06/13/2024 | Date of stock option grant and first vesting installment. |
| 06/12/2034 | Expiration date of the stock options. |
| 06/18/2024 | Date Form 4 was filed. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.